NO323277B1 - Ekspresjonsokende sekvenselementer (EASE) for eukaryote ekspresjonssystemer - Google Patents
Ekspresjonsokende sekvenselementer (EASE) for eukaryote ekspresjonssystemer Download PDFInfo
- Publication number
- NO323277B1 NO323277B1 NO19983102A NO983102A NO323277B1 NO 323277 B1 NO323277 B1 NO 323277B1 NO 19983102 A NO19983102 A NO 19983102A NO 983102 A NO983102 A NO 983102A NO 323277 B1 NO323277 B1 NO 323277B1
- Authority
- NO
- Norway
- Prior art keywords
- expression
- nucleotides
- dna
- protein
- ease
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 79
- 230000002708 enhancing effect Effects 0.000 title claims description 3
- 239000013604 expression vector Substances 0.000 claims abstract description 35
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 34
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 34
- 210000004027 cell Anatomy 0.000 claims description 123
- 108090000623 proteins and genes Proteins 0.000 claims description 73
- 108020004414 DNA Proteins 0.000 claims description 72
- 239000002773 nucleotide Substances 0.000 claims description 58
- 125000003729 nucleotide group Chemical group 0.000 claims description 58
- 102000004169 proteins and genes Human genes 0.000 claims description 48
- 230000000694 effects Effects 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 33
- 108010022394 Threonine synthase Proteins 0.000 claims description 29
- 102000004419 dihydrofolate reductase Human genes 0.000 claims description 27
- 239000012634 fragment Substances 0.000 claims description 27
- 239000013612 plasmid Substances 0.000 claims description 21
- 239000003550 marker Substances 0.000 claims description 13
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 12
- 238000011084 recovery Methods 0.000 claims description 6
- 241000699802 Cricetulus griseus Species 0.000 claims description 5
- 210000001672 ovary Anatomy 0.000 claims description 5
- 108700024394 Exon Proteins 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 10
- 235000018102 proteins Nutrition 0.000 description 34
- 239000013598 vector Substances 0.000 description 22
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 17
- 239000003623 enhancer Substances 0.000 description 17
- 229960000485 methotrexate Drugs 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 13
- 238000003556 assay Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 230000010354 integration Effects 0.000 description 10
- 210000004962 mammalian cell Anatomy 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 8
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- 238000011161 development Methods 0.000 description 7
- 238000010367 cloning Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 108010029697 CD40 Ligand Proteins 0.000 description 4
- 102100032937 CD40 ligand Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000005757 colony formation Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 230000010474 transient expression Effects 0.000 description 4
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 108700014844 flt3 ligand Proteins 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 210000001938 protoplast Anatomy 0.000 description 3
- 239000006152 selective media Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000011426 transformation method Methods 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
- 102000055025 Adenosine deaminases Human genes 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108091062157 Cis-regulatory element Proteins 0.000 description 2
- 101150074155 DHFR gene Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000710188 Encephalomyocarditis virus Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010048723 Multiple-drug resistance Diseases 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000012983 Dulbecco’s minimal essential medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108700001097 Insect Genes Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 101100278853 Mus musculus Dhfr gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 102100026123 Pirin Human genes 0.000 description 1
- -1 Polyethylene Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000001651 autotrophic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000003606 oligomerizing effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 238000012920 two-step selection procedure Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Control Of Indicators Other Than Cathode Ray Tubes (AREA)
- Amplifiers (AREA)
- Error Detection And Correction (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58650996A | 1996-01-11 | 1996-01-11 | |
| PCT/US1997/000483 WO1997025420A1 (en) | 1996-01-11 | 1997-01-10 | Expression augmenting sequence elements (ease) for eukaryotic expression systems |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO983102D0 NO983102D0 (no) | 1998-07-03 |
| NO983102L NO983102L (no) | 1998-09-08 |
| NO323277B1 true NO323277B1 (no) | 2007-02-26 |
Family
ID=24346030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19983102A NO323277B1 (no) | 1996-01-11 | 1998-07-03 | Ekspresjonsokende sekvenselementer (EASE) for eukaryote ekspresjonssystemer |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US6027915A (de) |
| EP (1) | EP0873405B1 (de) |
| JP (1) | JP3495375B2 (de) |
| KR (1) | KR19990077015A (de) |
| AT (1) | ATE275628T1 (de) |
| AU (1) | AU708981B2 (de) |
| CA (1) | CA2241174C (de) |
| DE (1) | DE69730592T2 (de) |
| DK (1) | DK0873405T3 (de) |
| ES (1) | ES2227669T3 (de) |
| NO (1) | NO323277B1 (de) |
| NZ (1) | NZ330926A (de) |
| PT (1) | PT873405E (de) |
| WO (1) | WO1997025420A1 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT873405E (pt) * | 1996-01-11 | 2005-01-31 | Immunex Corp | Elementos de sequencia que aumentam a expressao (ease) para sistemas de expressao eucarioticos |
| US6596514B2 (en) * | 1996-01-11 | 2003-07-22 | Immunex Corporation | Expression augmenting sequence elements (EASE) for eukaryotic expression systems |
| EP0951551B9 (de) | 1996-12-23 | 2012-12-26 | Immunex Corporation | Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie |
| US6521419B1 (en) | 1998-09-22 | 2003-02-18 | Kanakaraju Koduri | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| US6800457B2 (en) | 1998-09-22 | 2004-10-05 | Bristol-Myers Squibb Company | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| EP1222298B1 (de) * | 1999-10-13 | 2005-12-07 | Immunex Corporation | Vektoren und verfahren für rekombinante proteinexpression |
| JP2003535037A (ja) | 1999-12-23 | 2003-11-25 | ザイモジェネティクス，インコーポレイティド | 炎症を治療する方法 |
| KR100450266B1 (ko) * | 2002-01-16 | 2004-09-30 | 주식회사 엘지생명과학 | 유전자 발현 동물세포 제조용 바이시스트로닉 벡터 및이를 포함하는 세포주 그리고 이를 이용한 항체단백질의생산방법 |
| AU2003228383A1 (en) * | 2002-04-09 | 2003-10-27 | Global Biotech Inc. | Human tissue urokinase type plasminogen activator production |
| WO2004007664A2 (en) * | 2002-05-28 | 2004-01-22 | Maxygen, Inc. | Nucleic acid vectors |
| JP2005031812A (ja) * | 2003-07-08 | 2005-02-03 | Toshiba Corp | 画像形成装置およびその制御方法 |
| KR100807312B1 (ko) | 2005-10-22 | 2008-02-28 | (주)리즈바이오텍 | 재조합 인간 인슐린 유사 성장 인자 결합 단백질-3의 생산정제 방법 |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| EP2500416A1 (de) | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Verbesserungen an Zellkulturen |
| MY161866A (en) | 2006-09-13 | 2017-05-15 | Abbvie Inc | Cell culture improvements |
| SG182953A1 (en) | 2007-03-30 | 2012-08-30 | Abbott Lab | Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells |
| US8815794B2 (en) | 2008-08-28 | 2014-08-26 | The Research Foundation For The State University Of New York | Treatment of amyloidoses using myelin basic protein and fragments thereof |
| JP4568378B2 (ja) * | 2008-08-29 | 2010-10-27 | 東洋紡績株式会社 | 遺伝子発現安定化エレメント |
| US20100183620A1 (en) | 2008-11-26 | 2010-07-22 | Kaumudi Bhawe | Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2 |
| US9284563B2 (en) | 2009-06-15 | 2016-03-15 | Cellagenics B.V. | Stringent selectable markers |
| CN103038352B (zh) * | 2010-06-15 | 2015-12-16 | 萨拉基尼克有限公司 | 用于增强基因表达的新型基因间元件 |
| KR101599138B1 (ko) * | 2014-06-17 | 2016-03-03 | 한국생명공학연구원 | 재조합 단백질 발현 증진을 위한 유전자 절편을 포함하는 벡터 및 이의 용도 |
| WO2016003368A1 (en) * | 2014-07-01 | 2016-01-07 | Agency For Science, Technology And Research | Optimized vectors for the production of recombinant proteins |
| WO2020068631A1 (en) * | 2018-09-24 | 2020-04-02 | Merck Sharp & Dohme Corp. | Expression vectors for eukaryotic expression systems |
| CN113195712A (zh) | 2018-12-10 | 2021-07-30 | 美国安进公司 | 突变型piggyBac转座酶 |
| WO2020132382A1 (en) | 2018-12-21 | 2020-06-25 | Merck Sharp & Dohme Corp. | Expression vectors for eukaryotic expression systems |
| BR112021024665A2 (pt) * | 2019-06-07 | 2022-02-08 | Biocon Biologics Ltd | Vetores de expressão em mamíferos |
| TW202233660A (zh) | 2020-10-30 | 2022-09-01 | 美商安進公司 | 過表現胰島素樣生長因子受體突變體以調節ｉｇｆ補充 |
| WO2022140389A1 (en) | 2020-12-22 | 2022-06-30 | Amgen Inc. | Cell culture method |
| EP4351722A1 (de) | 2021-06-10 | 2024-04-17 | Amgen Inc. | Manipulierte nrg-1-varianten mit verbesserter selektivität gegenüber erbb4 aber nicht gegen erbb3 |
| TW202328442A (zh) | 2021-09-10 | 2023-07-16 | 美商安進公司 | 平臺宿主對ｉｇｆ—培養基之適應 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3730246A1 (de) * | 1987-09-09 | 1989-06-01 | Boehringer Mannheim Gmbh | Expressionsvektor und verfahren zur expression von heterologen proteinen in saeugerzellen |
| PT873405E (pt) * | 1996-01-11 | 2005-01-31 | Immunex Corp | Elementos de sequencia que aumentam a expressao (ease) para sistemas de expressao eucarioticos |
-
1997
- 1997-01-10 PT PT97902909T patent/PT873405E/pt unknown
- 1997-01-10 EP EP97902909A patent/EP0873405B1/de not_active Expired - Lifetime
- 1997-01-10 JP JP52544497A patent/JP3495375B2/ja not_active Expired - Fee Related
- 1997-01-10 KR KR1019980705146A patent/KR19990077015A/ko not_active Application Discontinuation
- 1997-01-10 CA CA002241174A patent/CA2241174C/en not_active Expired - Lifetime
- 1997-01-10 ES ES97902909T patent/ES2227669T3/es not_active Expired - Lifetime
- 1997-01-10 AU AU16973/97A patent/AU708981B2/en not_active Ceased
- 1997-01-10 DE DE69730592T patent/DE69730592T2/de not_active Expired - Lifetime
- 1997-01-10 DK DK97902909T patent/DK0873405T3/da active
- 1997-01-10 WO PCT/US1997/000483 patent/WO1997025420A1/en active IP Right Grant
- 1997-01-10 AT AT97902909T patent/ATE275628T1/de active
- 1997-01-10 NZ NZ330926A patent/NZ330926A/xx not_active IP Right Cessation
- 1997-01-13 US US08/785,150 patent/US6027915A/en not_active Expired - Lifetime
-
1998
- 1998-07-03 NO NO19983102A patent/NO323277B1/no not_active IP Right Cessation
-
1999
- 1999-11-05 US US09/435,377 patent/US6312951B1/en not_active Expired - Lifetime
-
2000
- 2000-09-12 US US09/660,299 patent/US6309841B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2241174C (en) | 2006-09-12 |
| AU1697397A (en) | 1997-08-01 |
| US6309841B1 (en) | 2001-10-30 |
| KR19990077015A (ko) | 1999-10-25 |
| WO1997025420A1 (en) | 1997-07-17 |
| DE69730592D1 (de) | 2004-10-14 |
| EP0873405A4 (de) | 2001-10-17 |
| ATE275628T1 (de) | 2004-09-15 |
| AU708981B2 (en) | 1999-08-19 |
| NZ330926A (en) | 1999-11-29 |
| EP0873405B1 (de) | 2004-09-08 |
| JP2000503205A (ja) | 2000-03-21 |
| US6312951B1 (en) | 2001-11-06 |
| ES2227669T3 (es) | 2005-04-01 |
| US6027915A (en) | 2000-02-22 |
| CA2241174A1 (en) | 1997-07-17 |
| PT873405E (pt) | 2005-01-31 |
| NO983102D0 (no) | 1998-07-03 |
| JP3495375B2 (ja) | 2004-02-09 |
| DK0873405T3 (da) | 2005-01-17 |
| NO983102L (no) | 1998-09-08 |
| EP0873405A1 (de) | 1998-10-28 |
| DE69730592T2 (de) | 2005-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO323277B1 (no) | Ekspresjonsokende sekvenselementer (EASE) for eukaryote ekspresjonssystemer | |
| CA2005016C (en) | Dna fragment containing promoter region for human polypeptide chain elongation factor-1.alpha. and expression plasmid containing the dna fragment | |
| US9944934B2 (en) | Inducible eukaryotic expression system | |
| Damke et al. | [24] Tightly regulated and inducible expression of dominant interfering dynamin mutant in stably transformed HeLa cells | |
| Bieker et al. | The erythroid Krüppel-like factor transactivation domain is a critical component for cell-specific inducibility of a β-globin promoter | |
| KR101183764B1 (ko) | 프로모터 | |
| US6306605B1 (en) | Methods for making recombinant cells | |
| US7745189B2 (en) | Regulatable growth of filamentous fungi | |
| JP2001186897A (ja) | 相同組換え法を用いてのタンパク質の生成 | |
| EA010863B1 (ru) | Отбор клеток-хозяев, экспрессирующих белок на высоких уровнях | |
| US6743622B2 (en) | Homologous recombination antibody expression system for murine cells | |
| Pieper et al. | Regulation of vimentin expression in cultured epithelial cells | |
| Jones et al. | Regulation of adenovirus transcription by an E1a gene in microinjected Xenopus laevis oocytes | |
| Yoshikawa et al. | Flow cytometry: an improved method for the selection of highly productive gene‐amplified CHO cells using flow cytometry | |
| Gourdji et al. | The rat prolactin gene: a target for tissue-specific and hormone-dependent transcription factors | |
| JPH07250689A (ja) | タンパク質−タンパク質相互作用を検出するためのペリプラズム膜結合系 | |
| JP6960409B2 (ja) | プロモーター | |
| Ko et al. | An auto-inducible vector conferring high glucocorticoid inducibility upon stable transformant cells | |
| Stacey et al. | Rescue of type I collagen-deficient phenotype by retroviral-vector-mediated transfer of human pro alpha 1 (I) collagen gene into Mov-13 cells | |
| Kulke et al. | Biological properties of the deer papillomavirus E5 gene in mouse C127 cells: growth transformation, induction of DNA synthesis, and activation of the platelet-derived growth factor receptor | |
| CN102239261A (zh) | 人工染色体载体 | |
| CN104975018B (zh) | 一种新型增强子及其应用 | |
| Reik et al. | Enhanced protein production by engineered zinc finger proteins | |
| US11618904B2 (en) | Promoter with an enriched Cytosine-Guanine dinucleotide region, vectors, cellular lines, method for producing recombinant protein | |
| CN114561430B (zh) | 人源化细胞瞬时表达用表达载体、表达系统、构建方法及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |